featured
131I-Apamistamab Before Allogeneic HCT vs Conventional Care for Relapsed/Refractory AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML
J. Clin. Oncol 2024 Sep 19;[EPub Ahead of Print], B Gyurkocza, R Nath, S Seropian, H Choe, MR Litzow, C Abboud, N Koshy, P Stiff, B Tomlinson, S Abhyankar, J Foran, P Hari, G Chen, Z Al-Kadhimi, P Kebriaei, M Sabloff, JJ Orozco, K Jamieson, M Silverman, K Van Besien, M Schuster, AD Law, K Larkin, N Pandit-Taskar, SD Rowley, P Munshi, R Cook, MY Levy, HM Lazarus, BM Sandmaier, JM Pagel, V Reddy, J MacDougall, K McNamara, J Spross, E Haeuber, M Vusirikala, A Nahar, A Desai, S GiraltFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.